Jul 2026· Clinical and Translational Oncology· 0 citations· 81 references
Medicine
TL;DR
The potential of siRNA as a promising therapeutic tool in oncology is highlighted while emphasizing the need for further research to optimize its clinical translation.
Small interfering RNA (siRNA) and messenger RNA (mRNA) therapeutics represent transformative approaches in precision pharmacology, enabling targeted gene silencing and protein expression, respectively. This review provides a comprehensive analysis of their molecular mechanisms, delivery strategies, clinical application...
Ritu Dahiya, A. Singh, Pooja Mathur et al.· Current Gene Therapy· 0 citations
Onpattro, the first FDA-approved RNAi therapy, is highlighted, Onpattro’s clinical development is highlighted, compares delivery platforms, discusses translational challenges, and emerging technologies that will guide the next generation of RNAi nanomedicines in personalized therapy are examined.
Dilpreet Singh, Satvir Singh, Nitin Tandon et al.· Iranian Journal of Basic Med...· 1 citation
Overall, siRNA-based strategies may play a crucial role in the future development of precision-oriented therapeutic frameworks in GC research, and this review emphasizes the integration of molecular target selection with delivery system design in a GC-specific context.
Gheysar Seifollahnezhad, B. Erdağ· Experimental oncology· 0 citations
The mechanisms of CRISPR-Cas9 gene editing, recent technological advancements, and prospects for cancer management are explored and insights into strategies for precise delivery, improved targeting accuracy, and the regulatory considerations surrounding CRISPR-Cas9 for oncological applications are provided.
Nikhil Rawal, Shruti Batra, Tanu Sharma et al.· Current pharmaceutical desig...· 0 citations
This review critically summarizes recent developments in advanced nanocarriers for cancer therapy, emphasizing their design principles, therapeutic applications, clinical translation, and the key challenges influencing their future clinical adoption.
Aliya Rehmani, Palak Ghanshyam Rahangdale, Payal Dilip Meshram· Journal of Drug Delivery and...· 0 citations
The present review examines the possibilities of using protein-based nanomedicine in breast cancer treatment by looking at targeted drug delivery, immune modulation, and the mechanism of enhanced permeability and retention (EPR) for the precise targeting of the tumour.
S. H. Almurisi, Chua-Hsuan Kai, Foo Yoong Kit et al.· Nano LIFE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.